Patents by Inventor Dai Cheng

Dai Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260242395
    Abstract: Provided herein are novel compounds (e.g., Formula I), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK4 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.
    Type: Application
    Filed: July 28, 2023
    Publication date: August 20, 2026
    Inventors: Dai CHENG, Yang ZHOU, Sen ZENG, Qiming YUE, Zhixiang HE, Xiaohang YIN, Zeqiang XIE, Wei HAN, Pengfei LEI, Xiaobo ZHOU, Yangyin XIE, Yuhong FU, Jianwei CHE, Guosheng WU
  • Publication number: 20260234111
    Abstract: Provided are isotopologues of aminoheteroaryl compounds for inhibiting cyclin-dependent kinases, processes for the preparation of the compounds, pharmaceutical compositions comprising the compounds, and methods of treatment of diseases and disorders using the compounds or pharmaceutical compositions.
    Type: Application
    Filed: December 23, 2025
    Publication date: August 13, 2026
    Inventors: Dai CHENG, Xiaohang YIN, Zeqiang XIE
  • Publication number: 20250320185
    Abstract: Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.
    Type: Application
    Filed: November 25, 2024
    Publication date: October 16, 2025
    Inventors: Dai CHENG, Qiming YUE, Sen ZENG, Zhixiang HE, Xiaobo ZHOU, Yang ZHOU, Zeqiang XIE, Xiaohang YIN, Qiang DING
  • Publication number: 20250026763
    Abstract: Provided herein are compounds having an amide-based backbone that is connected to multiple ring structures, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions thereof, and method of use thereof as selective allosteric inhibitors of EGFR mutants.
    Type: Application
    Filed: May 24, 2024
    Publication date: January 23, 2025
    Inventors: Ming YU, Yipin LU, Dai CHENG, Fang LI, Lina GU, Tiansheng WANG
  • Publication number: 20250002480
    Abstract: Provided herein are novel compounds, pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.
    Type: Application
    Filed: May 21, 2024
    Publication date: January 2, 2025
    Inventors: Dai CHENG, Qiang DING, Tao ZHANG
  • Publication number: 20240335443
    Abstract: Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to Tyrosine kinase 2 (TYK2). The compounds herein are typically TYK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as an autoimmune disorder or an inflammatory disorder, e.g., psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and/or systemic lupus erythematosus.
    Type: Application
    Filed: January 18, 2022
    Publication date: October 10, 2024
    Inventors: Dai Cheng, Sen Zeng, Qiming Yue, Zeqiang Xie
  • Publication number: 20240246944
    Abstract: Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to Tyrosine kinase 2 (TYK2). The compounds herein are typically TYK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as an autoimmune disorder or an inflammatory disorder, e.g., psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, and/or systemic lupus erythematosus.
    Type: Application
    Filed: July 13, 2021
    Publication date: July 25, 2024
    Inventors: Dai Cheng, Qiang Ding
  • Publication number: 20240166635
    Abstract: Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.
    Type: Application
    Filed: November 26, 2021
    Publication date: May 23, 2024
    Inventors: Dai Cheng, Qiang Ding, Zhixiang He, Xiaobo Zhou, Yang Zhou, Xiaohang Yin, Zeqiang Xie
  • Publication number: 20230128198
    Abstract: Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 27, 2023
    Inventors: Dai CHENG, Mingming CHEN, Amin LI, Haijun LI, Guiqun YANG
  • Patent number: 11384066
    Abstract: Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: July 12, 2022
    Assignee: Jacobio Pharmaceuticals Co., Ltd.
    Inventors: Dai Cheng, Mingming Chen, Amin Li, Haijun Li, Guiqun Yang
  • Patent number: 10251893
    Abstract: The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), wherein A1, Y and Z all represent rings.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 9, 2019
    Assignee: Novartis AG
    Inventors: Dai Cheng, Wenqi Gao, Dong Han, Shifeng Pan, Guobao Zhang
  • Publication number: 20180000832
    Abstract: The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), wherein A1, Y and Z all represent rings.
    Type: Application
    Filed: September 8, 2017
    Publication date: January 4, 2018
    Inventors: Dai CHENG, Wenqi GAO, Dong HAN, Shifeng PAN, Guobao ZHANG
  • Publication number: 20160082014
    Abstract: The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), wherein A1, Y and Z all represent rings.
    Type: Application
    Filed: December 8, 2015
    Publication date: March 24, 2016
    Applicant: NOVARTIS AG
    Inventors: Dai CHENG, Wenqi GAO, Dong HAN, Shifeng PAN, Guobao ZHANG
  • Patent number: 9238646
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: January 19, 2016
    Assignee: NOVARTIS AG
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • Patent number: 9216964
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 22, 2015
    Assignee: Novartis AG
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan
  • Patent number: 9181235
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R1, R2, R3 are as defined herein.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS AG
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan, Lichun Shen, Rajender Reddy Leleti
  • Publication number: 20130310375
    Abstract: The present invention relates to compositions and methods for modulating the Wnt signaling pathway.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • Publication number: 20130296333
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Application
    Filed: July 9, 2013
    Publication date: November 7, 2013
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan
  • Patent number: 8546396
    Abstract: The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: October 1, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Guobao Zhang, Dong Han, Wenqi Gao, Shifeng Pan
  • Patent number: 8507491
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: August 13, 2013
    Assignee: IRM LLC
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan